Cargando…
Oral immunotherapy combined with omalizumab for high–risk cow’s milk allergy: a randomized controlled trial
We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow’s milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6...
Autores principales: | Takahashi, Masaya, Soejima, Kazuhiko, Taniuchi, Shoichiro, Hatano, Yasuko, Yamanouchi, Sohsaku, Ishikawa, Hideki, Irahara, Makoto, Sasaki, Youhei, Kido, Hiroshi, Kaneko, Kazunari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727171/ https://www.ncbi.nlm.nih.gov/pubmed/29234055 http://dx.doi.org/10.1038/s41598-017-16730-6 |
Ejemplares similares
-
Author Correction: Oral immunotherapy combined with omalizumab for high–risk cow’s milk allergy: a randomized controlled trial
por: Takahashi, Masaya, et al.
Publicado: (2018) -
Successful desensitization in a boy with severe cow’s milk allergy by a combination therapy using omalizumab and rush oral immunotherapy
por: Takahashi, Masaya, et al.
Publicado: (2015) -
Two-weeks-sustained unresponsiveness by oral immunotherapy using microwave heated cow’s milk for children with cow’s milk allergy
por: Takahashi, Masaya, et al.
Publicado: (2016) -
Erratum to: Two-weeks-sustained unresponsiveness by oral immunotherapy using microwave heated cow’s milk for children with cow’s milk allergy
por: Takahashi, Masaya, et al.
Publicado: (2016) -
Immunotherapy for cow's milk allergy
por: Taniuchi, Shoichiro, et al.
Publicado: (2017)